Top Markets
Coin of the day
Fusion Antibodies plc Fusion Antibodies plc

Fusion Antibodies plc

FAB
Hisse Senetlerindeki Sıralama #20442
Fusion Antibodies plc, a contract research organization, engages in the... Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. It offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. The company serves pharmaceutical, biotech, and diagnostic companies. It has a collaboration partnership with Celonic AG. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.
Hisse Fiyatı
$0.16328419
Piyasa Değeri
$204.14K
Değişim (1 gün)
4.35%
Değişim (1 yıl)
102.45%
Ülke
GB
Ticaret Fusion Antibodies plc (FAB)

Kategori

Fusion Antibodies plc (FAB) için kazanç
Sep 2025 itibarıyla kazanç TTM: $-2.06M
Fusion Antibodies plc şirketinin en son finansal raporlarına göre, mevcut kazancı $-2.06M'dir. 2024 yılında şirket $-2.89M kazanç elde etti, bu 2023 yılındaki $-3.53M kazanca göre önceki yıla göre artış. Bu sayfada gösterilen kazanç, faiz ve vergiler öncesi kazançtır; yani EBIT.
Fusion Antibodies plc için kazanç geçmişi 2013 - 2026
Her yılın sonundaki kazanç
Yıl Kazanç Değiştir
2026 (TTM) $-2.06M -10.23%
2025 $-2.30M -20.56%
2024 $-2.89M -18.12%
2023 $-3.53M 101.40%
2022 $-1.75M 0.58%
2021 $-1.74M 30.88%
2020 $-1.33M -31.84%
2019 $-1.95M 95.89%
2018 $-997.05K -731.20%
2017 $157.96K 304.33%
2016 $39.07K -126.49%
2015 $-147.46K -26.55%
2014 $-200.78K -72.11%
2013 $-719.78K 0.00%
Benzer şirketler veya rakipler için kazanç
Şirket Kazanç Kazanç Farkı Ülke
$20.46B -992,770.77%
DK
$4.64B -225,408.48%
US
$5.23B -253,916.57%
US
$2.14B -103,830.35%
BE
$1.45B -70,512.80%
NL